‘Overpriced’ Antifungal Drug Seized In Kothagudem

Hyderabad: As part of stepped-up surveillance against overcharging of essential medicines, the Drugs Control Administration (DCA), Telangana, officials have seized ‘overpriced’ antifungal drug ‘GRISOLAB-250’ Griseofulvin tablets-250 mg during a surprise check in Kothagudem on Tuesday.

The worth of the stock seized during the raid is ₹4,095, according to a press release. The seized product, manufactured by Laborate Pharmaceuticals India Ltd, Himachal Pradesh, and marketed by Gpp Axalade, Salwan, Haryana, bears MRP as ₹65 for 10 tablets on the label of the product, which is a violation of Drugs (Prices Control) Order, 2013, the press release added. The ceiling price fixed by the Central government for the product ‘Griseofulvin tablets-250 mg’ is ₹17.7 for 10 tablets. Hence, the MRP i.e., including GST 12% should not be more than ₹19.83 for 10 tablets.

However, the pharmaceutical firm ‘overpriced’ the product. A strip of tablets has been charged excess of ₹45.17 per 10 tablets. Further investigation into the matter is underway and action will be taken against all the offenders as per the law, the DCA officials said.

In a separate incident, the DCA sleuths raided a medical shop named ‘Amaan Medical and General Stores’ allegedly operating without drug licence at Jaklair village in Narayanpet district. The officials seized an unauthorised stock of medicines including antibiotic injections, IV fluids, analgesics, antihypersensitive drugs and cough syrups worth ₹ 1.20 lakh. Further investigation is in progress.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices